Bristol-Myers Squibb (United States)

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis

BACKGROUND: Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. He...

Evolution of treatment distribution and patient characteristics of muscle invasive bladder cancer patients: results from two multi-national real-world surveys

To describe the real-world clinical characteristics and treatment distribution of patients with muscle-invasive bladder cancer (MIBC), and to discuss how these patterns have evolved over time. Data were drawn two separate cohorts of the Adelphi Muscle Invasive Urothelial Cancer D...